L-4-chlorokynurenine (AV-101) / VistaGen  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
L-4-chlorokynurenine (AV-101) / VistaGen
NCT02484456: Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder

Completed
2
22
US
AV 101 (4-Chlorokynurenine), 4-Cl-KYN, Placebo Comparator
National Institute of Mental Health (NIMH)
Major Depression
02/19
12/19
ELEVATE, NCT03078322: AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression

Checkmark Topline results from the ELEVATE study in MDD
Nov 2019 - Nov 2019: Topline results from the ELEVATE study in MDD
Completed
2
180
US
AV-101, L-4-chlorokynurenine, Placebo
VistaGen Therapeutics, Inc.
Major Depressive Disorder
10/19
10/19
NCT04147949: AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia

Not yet recruiting
2
20
NA
AV-101, L-4-chlorokynurenine, Placebo
VistaGen Therapeutics, Inc.
Parkinson Disease, Dyskinesia, Medication-Induced, L-Dopa Causing Adverse Effects in Therapeutic Use
12/23
04/24
NCT03583554: Electrophysiological Biomarkers of AV-101

Completed
1/2
18
US
Placebo, Placebo oral dose, AV-101 720 mg, L-4-Chlorokynurenine, AV-101 1440 mg
Marijn Lijffijt, PhD, Michael E. DeBakey VA Medical Center, VistaGen Therapeutics, Inc.
Healthy
10/19
10/19

Download Options